
About Silence Therapeutics
Silence Therapeutics is a publicly listed company based in London (United Kingdom) founded in 1999. RNA therapeutics for hematology and cardiovascular diseases are developed. It operates in the Healthcare and Technology sectors. The company has 116 employees. Silence Therapeutics has completed 1 acquisition, including Intradigm Corporation. Its website silence-therapeutics.com draws about 14 thousand monthly visits. Its focus areas include High Tech, Nanotechnology, Nanotools and Genomics. Its legal entity is SILENCE THERAPEUTICS PLC.
Company details
Founded in 1999 and headquartered in London, United Kingdom, RNA therapeutics are developed by the company for hematology and cardiovascular diseases. The pipeline features gene silencing approaches, including one that targets the Lipoprotein(A) gene to reduce risks of heart disease and stroke, and another that silences the TMPRSS6 gene to regulate iron levels in the body. Operations focus on advancing these treatments through clinical development.
- Headquarters London, United Kingdom
- Employees 116
- Stage Public
- SectorsHealthcareTechnology
- Website silence-therapeutics.com
- Social LinkedIn X
- Legal Name Silence Therapeutics, Plc.
- Annual Revenue$559 K (USD)-98.71as on Dec 31, 2025
- Net Profit-$88.61 M (USD)-95.57as on Dec 31, 2025
- EBITDA-$81.73 M (USD)-66.84as on Dec 31, 2025
- Latest Funding Round$120M (USD), Post-IPO
May 2021
- InvestorsAstrazeneca
& 5 more
- Employee Count116
- Investments & Acquisitions
Funding Insights of Silence Therapeutics
- Total Rounds 11
- Last Round Post-IPO β $120M
- First Round $24.3M
(Dec 2009)
- Investors Count 6
Latest 10 of 11 funding rounds of Silence Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $120M | Post-IPO | β | β | |
| Feb 2021 | $45.5M | Post-IPO | β | β | |
| Apr 2020 | $99.07M | Post-IPO | β | β | |
| Jul 2019 | $5M | Post-IPO | β | β | |
| Apr 2015 | $58.2M | Post-IPO | β | β | β |
| Apr 2014 | $18.95M | Post-IPO | β | β | β |
| Apr 2013 | $28M | Post-IPO | β | β | β |
| Nov 2012 | $8M | Post-IPO | β | β | β |
| Jul 2012 | $8.5M | Post-IPO | β | β | β |
| May 2011 | $9.6M | Post-IPO | β | β | β |
6 investors in total: 6 institutional.
Investors in Silence Therapeutics
Silence Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Mallinckrodt Pharmaceuticals and Adage Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
| consonancecapital.com | ||||
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Specialty pharmaceutical products and diagnostic imaging agents are manufactured. | 1867 | mallinckrodt.com | St. Louis, United States |
Investor details for Silence Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Silence Therapeutics
46 people are tracked at Silence Therapeutics (22 in leadership, 12 in board & advisors, 12 in team); the tracked headcount is 116.
| Name | Role | Group |
|---|---|---|
J.P. Gabriel | Chief Technical Operations Officer | Leadership |
Rhonda Hellums | CFO | Leadership |
Clare Elliott Cgma Acma | Senior Director, Head Of Fp&a | Leadership |
Alberto Martinez | Senior Clinical Science Director | Leadership |
Henry Fok | Senior Director, Clinical Science | Leadership |
Lance Edwards | Vice President - Information Technology | Leadership |
John Paul Gabriel | Svp, Chief Technical Operations Officer | Leadership |
Craig Tooman | President, CEO & Executive Director | Leadership |
Gianine Abbattista Esposito | Svp, Chief Human Resources Officer | Leadership |
Eliot Morrison | Principal Scientist, Head Of Molecular Design Biology | Leadership |
Gareth Rees | Associate Director Clinical Operations | Leadership |
Rachael Mills | Vp, Head Of Clinical Operations | Leadership |
Marianna Anesti | Vice President Of Business Development | Leadership |
Curtis Rambaran | Chief Medical Officer, SVP | Leadership |
Lucas Bethge | Vp, Group Leader Oligonucleotide Chemistry | Leadership |
David Rider | Project Director | Leadership |
Manuela Aleku | Project Director | Leadership |
Olubunmi Oduwole | Associate Director Clinical Operations | Leadership |
Lavita Menezes | Director Clinical Operations | Leadership |
Joana Santos | Associate Director Business Development | Leadership |
26 more people are available in the full profile.
Complete people profiles for Silence Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Silence Therapeutics
Silence Therapeutics is a publicly listed company on the OTC with ticker symbol SLNCF in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Aug 2020
- Listed onNASDAQ: SLN
- Listed entitySilence Therapeutics, Plc.
- Exchange sectorCommercial services
- ISINGB00B9GTXM62
- Share price$2.63 (+11.44% on the day) · 2026-05-11
- Market capitalisation$329.2M
- EPS (diluted, trailing year)$-0.53
- Volume (last session)122
- Analyst consensusNo rating
Financials of Silence Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $559,000 | -$88.6M | -$81.7M |
| 2024 | $43.3M | -$45.3M | -$49.0M |
| 2023 | $31.6M | -$54.2M | -$51.8M |
| 2022 | $21.6M | -$49.9M | -$59.3M |
| 2021 | $17.1M | -$54.2M | -$62.4M |
Detailed financial statements for Silence Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Silence Therapeutics
Silence Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Intradigm Corporation.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops RNA interference (RNAi) therapeutics for the treatment of cancer. | intradigm.com | Palo Alto, United States | 2000 | Dec 2009 | β’β’β’β’ |
Complete acquisition details for Silence Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Silence Therapeutics
5 dated milestones of Silence Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Silence Therapeutics is founded.
- Funding First funding round of $24.3M.
- Acquisition Acquires Intradigm Corporation.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $120.0M.
Web traffic of Silence Therapeutics
The website of Silence Therapeutics (silence-therapeutics.com) receives about 13.8K visits a month.
- Monthly visits13.8K
▲ 96.6% vs previous month
Websites whose visitors overlap most with Silence Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
atugen.com | atugen.com | 100% | #14,513,602 | β | |
| benitec.com | 100% | 2.7K | #6,325,279 | View details | |
| sylentis.com | 99% | 3.9K | #4,931,838 | View details | |
rnaiweb.com | rnaiweb.com | 99% | β | ||
oligoengine.com | oligoengine.com | 99% | #12,501,139 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for Silence Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Silence Therapeutics (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Silence Therapeutics
Complete news archive for Silence Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Silence Therapeutics
Silence Therapeutics was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Silence Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Silence Therapeutics has 116 employees.
Annual revenue of Silence Therapeutics is $559K as on Dec 31, 2025.
Founded in 1999 and headquartered in London, United Kingdom, RNA therapeutics are developed by the company for hematology and cardiovascular diseases. The pipeline features gene silencing approaches, including one that targets the Lipoprotein(A) gene to reduce risks of heart disease and stroke, and another that silences the TMPRSS6 gene to regulate iron levels in the body. Operations focus on advancing these treatments through clinical development.
Yes, Silence Therapeutics is publicly traded on OTC under the ticker symbol SLNCF.
Silence Therapeutics has made 1 acquisition, including Intradigm Corporation.
Silence Therapeutics has 6 investors. Key investors include Astrazeneca, Mallinckrodt Pharmaceuticals, Adage Capital Management, BVF Partners, and Consonance Capital.
Silence Therapeutics operates through Silence Therapeutics Plc.
